Intravitreal Injection of Bevacizumab: Changes in Intraocular Pressure Related to Ocular Axial Length

Overview

Journal Jpn J Ophthalmol

Specialty Ophthalmology

Date 2012 Oct 25

PMID 23093311

Citations 17

Authors

Andrea Cacciamani

Francesco Oddone

Mariacristina Parravano

Fabio Scarinci

Marta Di Nicola

Giorgio Lofoco

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the immediate and short-term effects of intravitreal injection of 1.25 mg/0.05 ml of bevacizumab on intraocular pressure related to different ocular axial lengths.

Design: A prospective case series of consecutive patients referred to the Department of Ophthalmology, San Pietro-Fatebenefratelli Hospital, from September 2011 through January 2011.

Methods: Twenty-five patients (10 men and 15 women, mean age 70.2 ± 8.98 years) scheduled for intravitreal injection of bevacizumab for the treatment of neovascular age-related macular degeneration were enrolled in this study. Axial length was measured preoperatively using IOLMaster. Intraocular pressure was measured before injection, after 1 min and after 15 min using Tono-Pen XL tonometry.

Results: The mean intraocular pressure change following the intravitreal bevacizumab injection was 21.92 ± 6.95 mmHg after 1 min and 6.24 ± 3.77 mmHg after 15 min. The mean axial length of the examined eyes was 23.2 ± 1.06 mm. A good correlation was observed between the axial length and intraocular pressure rise after both 1 (R (2) = 0.752, p < 0.001) and 15 min (R (2) = 0.559, p < 0.001).

Conclusions: Patients undergoing intravitreal injection of 0.05 ml of bevacizumab can be exposed to intraocular pressure increases correlated to ocular axial length.

Citing Articles

Effect of Estimated Individual Vitreous Volume on Intraocular Pressure Spikes after Intravitreal Anti-Vascular Endothelial Growth Factors Injection.

Kocak N, Gurpinar A, Yeter V Ophthalmic Res. 2024; 68(1):108-116.

PMID: 39694020 PMC: 11844668. DOI: 10.1159/000543071.

Effect of Vitreous Reflux after Intravitreal Aflibercept Injection for Macular Edema with Branch Retinal Vein Occlusion: A Real-World Study.

Muto T, Sakamoto M, Machida S, Imaizumi S, Sekiryu T J Ophthalmol. 2024; 2024:7645490.

PMID: 39263211 PMC: 11390217. DOI: 10.1155/2024/7645490.

Background diseases and the number of previous intravitreal aflibercept injections on immediate intraocular pressure increase and vitreous reflux rate in phakic eyes.

Muto T, Machida S, Imaizumi S Int J Ophthalmol. 2024; 17(3):545-550.

PMID: 38721500 PMC: 11074166. DOI: 10.18240/ijo.2024.03.17.

Acute and subacute intraocular pressure and macular microvascular structure changes after intravitreal ranibizumab injection in eyes with branch retinal vein occlusion.

Li X, Chen Q, Yu X BMC Ophthalmol. 2023; 23(1):160.

PMID: 37072736 PMC: 10111652. DOI: 10.1186/s12886-023-02889-2.

Evaluation of short-term intraocular pressure changes after intravitreal injection of Conbercept in patients with diabetic macular edema.

Hu Y, Zeng Y, Yang J, Zeng X, Cao D, Ou B Front Pharmacol. 2022; 13:1025205.

PMID: 36578537 PMC: 9791090. DOI: 10.3389/fphar.2022.1025205.

References

Kojima T, Tamaoki A, Yoshida N, Kaga T, Suto C, Ichikawa K . Evaluation of axial length measurement of the eye using partial coherence interferometry and ultrasound in cases of macular disease. Ophthalmology. 2010; 117(9):1750-4. DOI: 10.1016/j.ophtha.2010.01.018. View

Gismondi M, Salati C, Salvetat M, Zeppieri M, Brusini P . Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma. 2009; 18(9):658-61. DOI: 10.1097/IJG.0b013e31819c4893. View

Boon C, Crama N, Klevering B, van Kuijk F, Hoyng C . Reflux after intravitreal injection of bevacizumab. Ophthalmology. 2008; 115(7):1270. DOI: 10.1016/j.ophtha.2008.02.021. View

Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I . Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand. 2007; 85(7):777-81. DOI: 10.1111/j.1600-0420.2007.00939.x. View

Frenkel M, Haji S, Frenkel R . Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol. 2010; 128(12):1523-7. DOI: 10.1001/archophthalmol.2010.297. View

Ueda T, Nawa Y, Hara Y . Relationship between the retinal thickness of the macula and the difference in axial length. Graefes Arch Clin Exp Ophthalmol. 2005; 244(4):498-501. DOI: 10.1007/s00417-005-1146-5. View

Falkenstein I, Cheng L, Freeman W . Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). Retina. 2007; 27(8):1044-7. DOI: 10.1097/IAE.0b013e3180592ba6. View

Wu H, Chen T . The effects of intravitreal ophthalmic medications on intraocular pressure. Semin Ophthalmol. 2009; 24(2):100-5. DOI: 10.1080/08820530902800397. View

Presta L, Chen H, OConnor S, Chisholm V, Meng Y, Krummen L . Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997; 57(20):4593-9. View

10.

Frenkel R, Mani L, Toler A, Frenkel M . Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol. 2007; 143(6):1034-5. DOI: 10.1016/j.ajo.2007.01.052. View

11.

Kim K, Jee D . Effect of the Honan intraocular pressure reducer on intraocular pressure increase following intravitreal injection using the tunneled scleral technique. Jpn J Ophthalmol. 2011; 55(6):632-7. DOI: 10.1007/s10384-011-0088-1. View

12.

Utman S, Dhillon B . Re: Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina. 2008; 28(4):667. DOI: 10.1097/IAE.0b013e31816577e1. View

13.

Kerimoglu H, Ozturk B, Bozkurt B, Okka M, Okudan S . Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection?. Acta Ophthalmol. 2009; 89(2):138-42. DOI: 10.1111/j.1755-3768.2009.01656.x. View

14.

Kim J, Mantravadi A, Hur E, Covert D . Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008; 146(6):930-4.e1. DOI: 10.1016/j.ajo.2008.07.007. View

15.

Avery R, Pieramici D, Rabena M, Castellarin A, Nasir M, Giust M . Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006; 113(3):363-372.e5. DOI: 10.1016/j.ophtha.2005.11.019. View

16.

Bakri S, Pulido J, McCannel C, Hodge D, Diehl N, Hillemeier J . Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond). 2007; 23(1):181-5. DOI: 10.1038/sj.eye.6702938. View

17.

Pallikaris I, Kymionis G, Ginis H, Kounis G, Christodoulakis E, Tsilimbaris M . Ocular rigidity in patients with age-related macular degeneration. Am J Ophthalmol. 2006; 141(4):611-5. DOI: 10.1016/j.ajo.2005.11.010. View

18.

Hollands H, Wong J, Bruen R, Campbell R, Sharma S, Gale J . Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol. 2007; 42(6):807-11. DOI: 10.3129/i07-172. View

19.

Tewari A, Dhalla M, Apte R . Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina. 2006; 26(9):1093-4. DOI: 10.1097/01.iae.0000254896.78766.74. View

20.

Tsui Y, Chiang C, Tsai Y . Paracentesis before intravitreal injection of bevacizumab. Can J Ophthalmol. 2008; 43(2):239. DOI: 10.3129/i08-033. View